Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$3.4 million.

  • CG Oncology's Change in Accured Expenses fell 18039.5% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 11255.47%. This contributed to the annual value of $5.5 million for FY2024, which is 3217.31% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's Change in Accured Expenses is -$3.4 million, which was down 18039.5% from $7.5 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Change in Accured Expenses peaked at $7.5 million during Q2 2025, and registered a low of -$4.1 million during Q1 2024.
  • For the 3-year period, CG Oncology's Change in Accured Expenses averaged around $1.3 million, with its median value being $1.5 million (2023).
  • In the last 5 years, CG Oncology's Change in Accured Expenses tumbled by 271202.53% in 2024 and then soared by 26353.46% in 2025.
  • CG Oncology's Change in Accured Expenses (Quarter) stood at $1.8 million in 2023, then skyrocketed by 89.98% to $3.3 million in 2024, then tumbled by 201.23% to -$3.4 million in 2025.
  • Its last three reported values are -$3.4 million in Q3 2025, $7.5 million for Q2 2025, and $836000.0 during Q1 2025.